Article: HairDX Announces Clinical Trial Of Genetically Tailored Therapy for Female Baldness.

IRVINE, Calif. -- Pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC (www.hairdx.com), today announced that it has received institutional review board (IRB) approval to begin a clinical trial of a genetically tailored therapy for female baldness (Androgenetic Alopecia).

"Our goal is to revolutionize the field of dermatology by innovating genetically tailored treatments to common skin disorders," said Andy Goren, Chairman and Chief Strategist of PharmaGenoma, Inc and HairDX, LLC.

HairDX will soon begin recruiting post menopausal women as patients for the study. Women who qualify for the study will undergo genetic ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!